Management and Directors

John Edwards (Executive Chair)

John Edwards has over 30 years of experience in discovery, development, and global commercialization of biopharmaceuticals, involving over 10 FDA approved biologics at a series of successful biotechnology companies. Most recently he helped lead Adnexus from a start-up to the $450M acquisition by BMS within 4 years, where he then continued with the company for next 3 years serving as President. Earlier, Mr. Edwards was VP Sales, Marketing, and Medical Affairs at Transkaryotic Therapies and had a 15-year tenure with Genetics Institute/Wyeth, where he held senior-level positions in R&D, manufacturing, and commercial operations. Currently, Mr. Edwards also serves as executive chairman of F-star and ImmuneXcite.  He started his career in R&D at Genzyme (pre-IPO). Mr. Edwards received his M.B.A. from Boston University and his B.S. in Chemical Engineering from the U. Massachusetts at Amherst. 

Barbara S. Fox, PhD (CEO and Director)

Dr. Fox is the founding CEO of Tilos Therapeutics. She has previously served as Entrepreneur-in-Residence at Partners Innovation Fund, founder and CEO of Avaxia Biologics, founder and CSO of Recovery Pharmaceuticals, VP Discovery and Immunology at ImmuLogic Pharmaceutical Corp., and Associate Professor of Rheumatology at the U. Maryland School of Medicine. Dr. Fox received her AB in chemistry from Bryn Mawr, her PhD in chemistry from MIT and trained as a post-doc in cellular immunology at the NIH. She was an EY Entrepreneur Of The Year™ 2014 Award finalist in New England.

Martin Heidecker, PhD (Director)

Dr. Heidecker joined the Boehringer Ingelheim Venture Fund in 2010 to invest in early innovative therapeutic life science companies. In October 2013, he established the US-office of BIVF in Cambridge, MA, where he is focusing on biotech seed-investments. He has 15 years of investing and commercial experience in both venture capital and global pharma companies. Prior to BIVF, Dr. Heidecker held several global roles in Marketing at Boehringer Ingelheim and Solvay Pharmaceuticals and was involved in the global launch of several products in the area of CNS. He began his career as an Investment Manager at Bayern Kapital, focusing on seed investments of biotech companies. Dr. Heidecker holds a PhD in Biology as well as a Master degree in Biology and Economics. 

Roger Kitterman (Director)

Mr. Kitterman is Vice President, Venture and Managing Partner of the Partners Innovation Fund. In this role, he leads the Innovation Fund and Licensing teams. Mr. Kitterman also serves as Executive Director of the Boston Biomedical Innovation Center. He has been with the Partners Innovation Fund, a $140 million fund investing in Partners spinouts, since its launch in 2008. He is an experienced venture capital investor with more than 20 years in the industry and has guided multiple venture-backed companies through the earliest stages of development. He has also been the startup CEO for three venture-backed companies and is a founder of Mass Medical Angels. He has previously served as a partner at life science-focused venture funds in the Boston area. Roger began his venture capital career in Eastern Europe with the Bulgarian- American Enterprise Fund, a $55 million venture capital fund. Mr. Kitterman holds an MBA in Finance and Business Development from the Columbia Business School and an AB from Harvard College. 

Jay Knowles (Director)

Mr. Knowles has more than 20 years in the biotech / pharma industry and has guided multiple early stage companies through drug discovery and development. He was previously CEO of X-BODY Biosciences (sold to Juno), an emerging biotech focused on generating antibodies against GPCRs and ion channels. Prior to this, he was Head, Platforms, Strategic Alliances for Novartis, where he led a team responsible for creating technology-based and drug discovery collaborations, forging a number of major strategic alliances with biotech companies. Mr. Knowles was President of Novalar Pharmaceuticals, a specialty pharmaceutical company that brought a drug from idea stage through the clinic and onto the market. He was also Vice President, Business Development, at Novacea and at Structural Genomix, and Director, Research and Development Planning at Vertex Pharmaceuticals. He has an MBA in Finance from Wharton Business School, an M.Sc. in Chemistry from UC Berkeley, and a BA with Distinction in Chemistry from Carleton College.

Scientific Advisors

Mary Helen Barcellos-Hoff, PhD

Dr. Barcellos-Hoff is Professor of Radiation Oncology at UC San Francisco where she also serves as Director of Radiation Biology and Vice Chair Research. Before joining UCSF in 2015, she was Professor of Radiation Oncology and Cell Biology at NYU School of Medicine. A main focus of Dr. Barcellos-Hoff's research has been to understand the biology of transforming growth factor β (TGFβ) in irradiated cells and tissues and in normal mammary gland development and to understand its contribution to radiation responses of tissues and tumors. She holds a BA from U. Chicago and a PhD from UCSF and completed post-doctoral training at UC Berkeley.

Dan Duda, DMD, PhD

Dr. Duda is Associate Professor of Tumor Biology, Harvard Medical School, Full Investigator at MGH Research Institute and Director of Translational Research in GI Radiation Oncology at Massachusetts General Hospital. Dr. Duda's research efforts focus on identifying the underpinnings of gastrointestinal, prostate and breast cancer progression to metastasis as well as of treatment resistance, by studying the biology of these tumors as well as their interaction with the stroma. The goal is to identify and validate targets for combination therapy (with radiation and immunotherapy) in preclinical studies, and conduct in parallel studies of biomarkers of response in correlative clinical studies. He is the author of 185 publications and recipient of multiple awards. Dr. Duda obtained his DMD from the University of Medicine Iasi, Romania and earned a PhD in Medical Sciences (Gastrointestinal Surgery) from Tohoku University Graduate School of Medicine, Sendai, Japan. He pursued postdoctoral training with Professor Rakesh K. Jain at MGH. 

Boris Hinz, PhD

Dr. Hinz is Distinguished Professor in Tissue Repair and Regeneration, University of Toronto, with a primary appointment in the Faculty of Dentistry and cross-appointments with the Faculty of Medicine, Department of Surgery and the Institute of Biomaterials and Biomedical Engineering. Before joining U. Toronto, Dr. Hinz led a research group at the Ecole Polytechnique Fédérale de Lausanne (EPFL), Switzerland. His research is aimed at understanding the role of contractile myofibroblasts in physiological tissue repair and in causing pathological tissue fibrosis. Dr Hinz has published 99 peer reviewed articles, 13 book chapters, was invited to >220 seminar and conference talks with 400 congress abstracts. His research has led to the creation of two startup companies specialized on anti-fibrotic coatings for silicone implants and novel “soft” cell culture devices. Dr. Hinz holds a PhD in Cell Biology and Theoretical Biology from the University of Bonn, Germany. He trained as a postdoctoral fellow with Dr. Giulio Gabbiani at University of Geneva, Switzerland.

Vijay Kuchroo, DVM, PhD

Dr. Kuchroo is Professor of Neurology at the Harvard Medical School and Associate Immunologist at the Brigham and Women’s Hospital. Dr. Kuchroo’s major research interests are autoimmune diseases, particularly the role of co-stimulation, genetic basis of EAE and type 1 diabetes and cell surface molecules and regulatory factors that contribute to susceptibility and resistance to autoimmune diseases. He serves on numerous advisory boards and editorial boards. Dr. Kuchroo is an inventor on 25 patents, has published over 340 original papers and numerous review articles and has been a founder of five biotech companies. Dr. Kuchroo received his DVM from the School of Veterinary Medicine, Hisar, India, his PhD from the University of Queensland, Brisbane (Australia) and was a Fogarty International Fellow at the NIH before joining the Department of Pathology, Harvard Medical School as a Research Fellow. 

Drew M. Pardoll, MD, PhD

Dr. Pardoll is the Abeloff Professor of Oncology, Medicine, Pathology and Molecular Biology and Genetics at the Johns Hopkins University, School of Medicine.  He is the Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy and Co-Director of the Cancer Immunology Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. His more than 300 articles cover cancer vaccines, gene therapies, cancer prevention technologies, recombinant immune modulatory agents for specific pathways that regulate immunity to cancer and infectious diseases. Dr. Pardoll discovered one of the two ligands for the PD-1 inhibitory receptor and leads the Hopkins cancer immunology program that developed PD-1 pathway-targeted antibodies, demonstrating their clinical activity in multiple cancer types. He serves on multiple scientific advisory boards and is a leading figure in the development of immunotherapies for cancer.  Dr. Pardoll received his MD and PhD at Johns Hopkins University and trained as a Medical Staff Fellow at the NIH.

Jonathan Schoenfeld, MD, MPhil, MPH

Dr. Jonathan Schoenfeld is a radiation oncologist at the Brigham and Women / Dana-Farber Cancer Center, Assistant Professor of Radiation Oncology at Harvard Medical School and the Director of Melanoma Radiation Oncology at the Dana-Farber Cancer Institute.  Dr. Schoenfeld’s research focuses on the design and implementation of clinical, epidemiologic and translational studies in head and neck and skin cancers.  He is actively evaluating the immunologic effects of radiation therapy and exploring treatments combining radiation with novel immune oncology agents. He received his medical degree from Harvard Medical School after completing a research fellowship at the University of Cambridge in the UK as a Gates Scholar. He performed his residency in radiation oncology in the Harvard Radiation Program and received a Master of Public Health in Clinical Effectiveness from the Harvard T.H. Chan School of Public Health.

Howard L. Weiner, MD

Howard L. Weiner is the Robert L. Kroc Professor of Neurology at the Harvard Medical School, Director and Founder of the Partners Multiple Sclerosis Center and Co-Director of the Center for Neurologic Diseases at the Brigham & Women’s Hospital. Dr. Weiner has pioneered the use of immunotherapy and the drug cyclophosphamide for the treatment of multiple sclerosis and has investigated immune abnormalities in the disease including the role of the innate immune system and regulatory T cells. Dr. Weiner's research on LAP-TGFβ and anti-LAP antibodies resulted in the establishment of Tilos Therapeutics in 2016. In 2004 Harvard Medical School honored Dr. Weiner with the establishment of the Howard L. Weiner Professor of Neurology Endowed Chair. Dr. Weiner is the 2007 recipient of the John Dystel Prize for Multiple Sclerosis Research awarded by the American Academy of Neurology and in 2008 received the Betty and David Koetser Memorial Prize as awarded by the Betty and David Koetser Foundation for Brain Research. In 2009, Dr. Weiner was presented the Award for Outstanding Research Achievement, Nature Biotechnology SciCafé, Nature Publications. Dr. Weiner holds a BA from Dartmouth College and an MD from U. Colorado School of Medicine.